Amylyx Pharmaceuticals, Inc.
AMLX
$14.44
-$0.44-2.96%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -41.28M | -33.00M | -34.39M | -41.44M | -35.91M |
| Total Depreciation and Amortization | 98.00K | 108.00K | 120.00K | 141.00K | 156.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.56M | 4.90M | 5.83M | 6.09M | 5.13M |
| Change in Net Operating Assets | -5.26M | 92.00K | -1.94M | 9.96M | -9.20M |
| Cash from Operations | -36.88M | -27.90M | -30.37M | -25.25M | -39.82M |
| Capital Expenditure | -- | -86.00K | -24.00K | -17.00K | -11.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 36.26M | 29.55M | 5.26M | 23.01M | -43.65M |
| Cash from Investing | 36.26M | 29.47M | 5.24M | 22.99M | -43.66M |
| Total Debt Issued | -- | -375.00K | 191.11M | 0.00 | 65.58M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 7.16M | 376.00K | 2.66M | 72.00K | 970.00K |
| Repurchase of Common Stock | -3.94M | -209.00K | -2.16M | -103.00K | -885.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 3.22M | -208.00K | 191.61M | -31.00K | 65.66M |
| Foreign Exchange rate Adjustments | -111.00K | 118.00K | 151.00K | 608.00K | 197.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2.49M | 1.48M | 166.63M | -1.68M | -17.62M |